Meeting
2018 Genitourinary Cancers Symposium
Role of mTORC2 and nitric oxide in bladder cancer invasion.
Authors
Divya Sahu
University of California San Diego, La Jolla, CA
Divya Sahu , Donna E. Hansel , Richard Klemke , Gerry Boss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 504)
DOI
10.1200/JCO.2018.36.6_suppl.504
Abstract #
504
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.
First Author: Alejandro Martinez
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer.
First Author: Nadine Houede
Poster
2024 ASCO Genitourinary Cancers Symposium
Identification and characterization of prognostic isoforms associated with bladder cancer outcomes.
First Author: Christopher Patsalis
Poster
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
First Author: Vincent D'Andrea